Swan Capital’s Haemonetics HAE Stock Holding History

Swan Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11	Closed	-$884	–	397
2024 Q3	$884	Buy	+11	New	+$889	﹤0.01%	273

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Swan Capital's HAE Position: Q4 2024 in Review

Swan Capital sold out of Haemonetics (HAE) in Q4 2024, closing a stake of 11 shares — an estimated $884 sold.

Swan Capital first reported a position in HAE in Q3 2024 and held it in 1 quarter. The position peaked at $884 in Q3 2024. 309 funds tracked by Wall St. Rank hold HAE as of Q4 2024.

Swan Capital reported no remaining Haemonetics position as of Q4 2024 after selling out during the quarter.
Swan Capital sold 11 Haemonetics shares in Q4 2024, an estimated $884.
Swan Capital first reported a position in Haemonetics in Q3 2024 and held it in 1 quarter.
Swan Capital's Haemonetics position peaked at $884 in Q3 2024.
309 funds tracked by Wall St. Rank held Haemonetics as of Q4 2024.

Based on Swan Capital's 13F filing for Q4 2024, filed 25 Feb 2025.